Standard

Ceramides As Potential New Predictors of the Severity of Acute Coronary Syndrome in Conjunction with SARS-CoV-2 Infection. / Lozhkina, N. G.; Gushchina, O. I.; Basov, N. V. et al.

In: Acta Naturae, Vol. 16, No. 2(61), 05.11.2024, p. 53-60.

Research output: Contribution to journal › Article › peer-review

Harvard

Lozhkina, NG, Gushchina, OI, Basov, NV, Gaisler, EV, Rogachev, AD, Sotnikova, YS, Patrushev, YV & Pokrovsky, AG 2024, 'Ceramides As Potential New Predictors of the Severity of Acute Coronary Syndrome in Conjunction with SARS-CoV-2 Infection', Acta Naturae, vol. 16, no. 2(61), pp. 53-60. https://doi.org/10.32607/actanaturae.27400

APA

Lozhkina, N. G., Gushchina, O. I., Basov, N. V., Gaisler, E. V., Rogachev, A. D., Sotnikova, Y. S., Patrushev, Y. V., & Pokrovsky, A. G. (2024). Ceramides As Potential New Predictors of the Severity of Acute Coronary Syndrome in Conjunction with SARS-CoV-2 Infection. Acta Naturae, 16(2(61)), 53-60. https://doi.org/10.32607/actanaturae.27400

Vancouver

Lozhkina NG, Gushchina OI, Basov NV, Gaisler EV, Rogachev AD, Sotnikova YS et al. Ceramides As Potential New Predictors of the Severity of Acute Coronary Syndrome in Conjunction with SARS-CoV-2 Infection. Acta Naturae. 2024 Nov 5;16(2(61)):53-60. doi: 10.32607/actanaturae.27400

Author

Lozhkina, N. G. ; Gushchina, O. I. ; Basov, N. V. et al. / Ceramides As Potential New Predictors of the Severity of Acute Coronary Syndrome in Conjunction with SARS-CoV-2 Infection. In: Acta Naturae. 2024 ; Vol. 16, No. 2(61). pp. 53-60.

BibTeX

@article{3e96354fd4f8497386906635615bde63,
title = "Ceramides As Potential New Predictors of the Severity of Acute Coronary Syndrome in Conjunction with SARS-CoV-2 Infection",
abstract = "Acute coronary events (ACEs) associated with a SARS-CoV-2 infection can significantly differ from classic ACEs. New biomarkers, such as ceramides, may help in the diagnosis and treatment of this disease. This study included 73 ACE patients for whom the SARS-CoV-2 infection was verified. Two subgroups were formed: the favorable outcome subgroup and the fatal outcome subgroup. Plasma samples were collected from all patients at the time of admission for a metabolomic analysis. The analysis of metabolites revealed that the ceramide levels were significantly lower in the fatal outcome subgroup than in the survivor subgroup. Therefore, determining ceramide levels in patients with ACEs in conjunction with COVID-19 may help assess the prognosis of these patients and manage their risks.",
keywords = "SARS-CoV-2 infection, acute coronary syndrome, ceramides, metabolomics, myocardial infarction",
author = "Lozhkina, {N. G.} and Gushchina, {O. I.} and Basov, {N. V.} and Gaisler, {E. V.} and Rogachev, {A. D.} and Sotnikova, {Yu S.} and Patrushev, {Yu V.} and Pokrovsky, {A. G.}",
year = "2024",
month = nov,
day = "5",
doi = "10.32607/actanaturae.27400",
language = "English",
volume = "16",
pages = "53--60",
journal = "Acta Naturae",
issn = "2075-8251",
publisher = "Park Media Ltd.",
number = "2(61)",

}

RIS

TY - JOUR

T1 - Ceramides As Potential New Predictors of the Severity of Acute Coronary Syndrome in Conjunction with SARS-CoV-2 Infection

AU - Lozhkina, N. G.

AU - Gushchina, O. I.

AU - Basov, N. V.

AU - Gaisler, E. V.

AU - Rogachev, A. D.

AU - Sotnikova, Yu S.

AU - Patrushev, Yu V.

AU - Pokrovsky, A. G.

PY - 2024/11/5

Y1 - 2024/11/5

N2 - Acute coronary events (ACEs) associated with a SARS-CoV-2 infection can significantly differ from classic ACEs. New biomarkers, such as ceramides, may help in the diagnosis and treatment of this disease. This study included 73 ACE patients for whom the SARS-CoV-2 infection was verified. Two subgroups were formed: the favorable outcome subgroup and the fatal outcome subgroup. Plasma samples were collected from all patients at the time of admission for a metabolomic analysis. The analysis of metabolites revealed that the ceramide levels were significantly lower in the fatal outcome subgroup than in the survivor subgroup. Therefore, determining ceramide levels in patients with ACEs in conjunction with COVID-19 may help assess the prognosis of these patients and manage their risks.

AB - Acute coronary events (ACEs) associated with a SARS-CoV-2 infection can significantly differ from classic ACEs. New biomarkers, such as ceramides, may help in the diagnosis and treatment of this disease. This study included 73 ACE patients for whom the SARS-CoV-2 infection was verified. Two subgroups were formed: the favorable outcome subgroup and the fatal outcome subgroup. Plasma samples were collected from all patients at the time of admission for a metabolomic analysis. The analysis of metabolites revealed that the ceramide levels were significantly lower in the fatal outcome subgroup than in the survivor subgroup. Therefore, determining ceramide levels in patients with ACEs in conjunction with COVID-19 may help assess the prognosis of these patients and manage their risks.

KW - SARS-CoV-2 infection

KW - acute coronary syndrome

KW - ceramides

KW - metabolomics

KW - myocardial infarction

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:001341930000006

UR - https://www.mendeley.com/catalogue/4f4280c9-66e6-3066-8e58-e1bfa4058786/

U2 - 10.32607/actanaturae.27400

DO - 10.32607/actanaturae.27400

M3 - Article

C2 - 39188263

VL - 16

SP - 53

EP - 60

JO - Acta Naturae

JF - Acta Naturae

SN - 2075-8251

IS - 2(61)

ER -

ID: 61237255